Accessibility: Skip TopNav
Initial Data from Phase 2a Arm Evaluating IMM-1-104 Monotherapy in Second Line Pancreatic Cancer as of December 5, 2024
Initial Data from Phase 2a Arm Evaluating IMM-1-104 Monotherapy in Second Line Pancreatic Cancer as of December 5, 2024
Format
JPEG
Source
Immuneering Corporation
Downloads
Original
Large
Medium
Small